Novartis AG Total Assets 2006-2018 | NVS

Novartis AG total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Novartis AG total assets for the quarter ending September 30, 2018 were $142.994B, a 5.94% increase year-over-year.
  • Novartis AG total assets for 2017 were $133.079B, a 2.27% increase from 2016.
  • Novartis AG total assets for 2016 were $130.124B, a 1.09% decline from 2015.
  • Novartis AG total assets for 2015 were $131.556B, a 4.92% increase from 2014.
Novartis AG Annual Total Assets
(Millions of US $)
2017 $133,079
2016 $130,124
2015 $131,556
2014 $125,387
2013 $126,254
2012 $124,191
2011 $117,496
2010 $123,318
2009 $95,505
2008 $78,299
2007 $75,452
2006 $68,008
2005 $57,732
Novartis AG Quarterly Total Assets
(Millions of US $)
Q3 2018 $142,994
Q2 2018 $142,058
Q1 2018 $135,524
Q4 2017 $133,079
Q3 2017 $134,972
Q2 2017 $133,749
Q1 2017 $131,986
Q4 2016 $130,124
Q3 2016 $134,007
Q2 2016 $131,436
Q1 2016 $132,448
Q4 2015 $131,556
Q3 2015 $132,927
Q2 2015 $135,413
Q1 2015 $134,935
Q4 2014 $125,387
Q3 2014 $125,377
Q2 2014 $125,768
Q1 2014 $125,332
Q4 2013 $126,254
Q3 2013 $124,594
Q2 2013 $121,072
Q1 2013 $121,011
Q4 2012 $124,191
Q3 2012 $121,219
Q2 2012 $118,492
Q1 2012 $119,411
Q4 2011 $117,496
Q3 2011 $121,377
Q2 2011 $125,915
Q1 2011 $127,218
Q4 2010 $123,318
Q3 2010 $124,628
Q2 2010 $96,924
Q1 2010 $95,795
Q4 2009 $95,505
Q3 2009 $90,686
Q2 2009 $84,274
Q1 2009 $77,970
Q4 2008 $78,299
Q3 2008 $82,020
Q2 2008 $83,399
Q1 2008 $76,318
Q4 2007 $75,452
Q3 2007 $76,936
Q2 2007 $70,621
Q1 2007 $68,324
Q4 2006 $68,008
Q3 2006 $66,862
Q2 2006 $65,929
Q1 2006 $58,848
Q4 2005 $57,732
Q3 2005 $54,670
Q2 2005 $53,043
Q1 2005 $49,646
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $200.739B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.718B 18.27
Pfizer (PFE) United States $264.307B 14.90
Merck (MRK) United States $208.739B 18.09
AbbVie (ABBV) United States $131.784B 11.70
Eli Lilly (LLY) United States $120.858B 21.25
Novo Nordisk (NVO) Denmark $112.280B 18.23
Sanofi (SNY) France $110.782B 13.72
AstraZeneca (AZN) United Kingdom $97.289B 12.08
GlaxoSmithKline (GSK) United Kingdom $93.444B 12.56
Bristol-Myers Squibb (BMY) United States $85.821B 14.13